Jubilant Life Sciences on Tuesday reported a 53 per cent increase in its first quarter net profit to Rs 77.12 crore from Rs 50.43 crore in the corresponding period of last year.

The EBDITA also moved up by 32 per cent to Rs 190 crore from Rs 93 crore. The company's net sales moved up by 16 per cent to Rs 948 crore.

International business from 75 countries contributed 69 per cent to net sales and reached at Rs 653 crore.

Sales from regulated markets of the US, Canada, Europe and Japan were at Rs 522 crore and amounted to 55 per cent of the net sales.

Sales from Europe and Japan increased by 50 per cent and followed by 16 growth in emerging markets. Its revenues in the US and Canada grew by 9 per cent.

Revenues for life science products increased by 19 per cent to Rs 739 crore from Rs 621 crore and contributed 78 per cent to sales. The share in revenue of life sciences ingredients was 64 per cent at Rs 608 crore with a growth of 16 per cent. The sales of generic products increased by 33 per cent to Rs 131 crore and contributed 14 per cent to sales.

revenue mix

Its life science services revenue was at Rs 205 crore. CMO contributed 16 per cent to the revenue mix at Rs 151 crore and drug discovery and development solutions reported Rs 52 crore in net sales, contributing over 5 per cent to the revenue mix for the quarter under review.

Mr Shyam S. Bhartia, chairman and managing director, Jubilant Life Sciences, said, “Our products business teams have performed well with a clear objective of aggressive sales growth; innovation led product launches, expansion in high growth geographies and increased vertical integration. Service business teams have taken focused margin improvement initiatives to substantially increase the profitability.”

The company filed three ANDAs in the US and received approval for one ANDA and a dossier. Its Roorkee plant received Japanese PMDA certification during the quarter.

Related Topics
comment COMMENT NOW